We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Test Can Rapidly Detect Infection Risk

By LabMedica International staff writers
Posted on 11 Dec 2013
Print article
Image: Microfluidic device for six assays under the microscope (Photo courtesy of BioMEMS Resource Center).
Image: Microfluidic device for six assays under the microscope (Photo courtesy of BioMEMS Resource Center).
A device has been created that is able to detect a person's risk of infection from a drop of blood within minutes, as opposed to current methods, which can take up to two hours.

Neutrophil chemotaxis is critical for defense against infections and its alterations could lead to chronic inflammation and tissue injury and the central role that transient alterations of neutrophil chemotaxis could have on patient outcomes calls for its quantification in the laboratory.

Scientists at the Massachusetts General Hospital (Boston, MA, USA) designed a microfluidic device to study neutrophil chemotaxis from a single droplet of whole blood, which has three main components: a chemokine side chambers (200 × 200 μm), a central whole-blood loading chamber, and migration channels containing red blood cell (RBC) filtering regions.

The filter for each migration channel consists of 10 short channels (length about 75 μm) connected horizontally through an approximately 200-μm-long channel to create 90 degree bending sections capable of trapping the RBCs in order to prevent them from dispersing into the rest of the migration channel. A gradient of the chemoattractant is established along the migration channels by diffusion between the chemoattractant chambers and the central loading chamber.

The assay was validated by comparing neutrophil chemotaxis from finger prick, venous blood and purified neutrophil samples. There was a consistent average velocity of 19 ± 6 μm/minute and directionality of 91.1% between the three sources. The team quantified the variability in neutrophil chemotaxis between healthy donors and found no significant changes over time. The novel whole blood device was also used to monitor neutrophil chemotaxis function in a patient with 24% total body surface area burns over a three-week treatment period.

Daniel Irmia, MD, PhD, an assistant professor at the BioMicro Electrical Mechanical Systems Resource Center (BioMEMS; Boston, MA, USA) and a senior author of the study said, “In many cases, it may not be enough to just count the neutrophils. If neutrophils do not migrate well and cannot reach inside the tissues, this situation could have the same consequences as a low neutrophil count.” The authors concluded that being able to measure patients' risk of infections in a matter of minutes from only a droplet of blood is a significant development and one that will improve current treatment. The study was published on October 2, 2013, in the journal Technology.

Related Links:

Massachusetts General Hospital
BioMEMS Resource Center 


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay
New
Centromere B Assay
Centromere B Test

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.